Stocksigma LogoStocksigma Logo

Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results

Akums Drugs and Pharmaceuticals reported a consolidated revenue from operations of ₹13,423.87 million for the quarter ended 30th Sep'26, up 31.9% YoY from

Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results

Akums Drugs and Pharmaceuticals Ltd · Change in Management · 02 Nov 2026, 11:04 pm

Akums Drugs Reports Strong Q2 FY27 Consolidated Financial Results Akums Drugs and Pharmaceuticals reported a consolidated revenue from operations of ₹13,423.87 million for the quarter ended 30th Sep'26, up 31.9% YoY from ₹10,175.30 million. Net profit attributable to owners surged 176.7% YoY to ₹1,128.51 million compared to ₹407.83 million in the prior-year period. Operating performance was led by its CDMO segment, which generated ₹11,148.66 million in external revenue. The company also fully utilized 100% of its ₹6,800.00 million IPO proceeds and appointed Sanjay Kumar as Senior Management Personnel effective 2nd Nov'26.

Original exchange filing (PDF)

More announcements from Akums Drugs and Pharmaceuticals Ltd

All Akums Drugs and Pharmaceuticals Ltd announcements